Results 11 to 20 of about 67,047,750 (221)

Heart Failure With Mid-range Ejection Fraction. [PDF]

open access: yesCurr Heart Fail Rep, 2020
Purpose of reviewTo describe the epidemiology, pathophysiology, management, and prognosis of patients with heart failure with mid-range ejection fraction (HFmrEF).Recent findingsIn 2013, The American Heart Association (AHA)/American College of Cardiology
Srivastava PK   +3 more
europepmc   +4 more sources

The Value of IGF-1 and IGFBP-1 in Patients With Heart Failure With Reduced, Mid-range, and Preserved Ejection Fraction [PDF]

open access: yesFrontiers in Cardiovascular Medicine, 2022
BackgroundPrevious studies have reported inconsistent results regarding the implications of deranged insulin-like growth factor 1 (IGF-1)/insulin-like growth factor-binding protein 1 (IGFBP-1) axis in patients with heart failure (HF).
Shaohua Guo   +7 more
doaj   +2 more sources

Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction [PDF]

open access: yesESC Heart Failure, 2020
Aims Spironolactone has been shown to improve outcomes in patients with heart failure (HF) with reduced ejection fraction (EF). We investigated whether the discharge use of spironolactone could be associated with better long‐term outcomes among patients ...
Nobuyuki Enzan   +6 more
doaj   +2 more sources

Heart failure with mid-range ejection fraction. Where are we today? [PDF]

open access: yesБългарска кардиология, 2021
Bulgarian Society of Cardiology adhere to the European Guidelines on Heart Failure (HF). The fi nalized studies and many debates and analyses after 2016 are prerequisite to creation of a new guideline for diagnosis and management on these patients.
Tzvetana Katova
doaj   +4 more sources

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition [PDF]

open access: yesCardiac Failure Review, 2020
The recent definition of an intermediate clinical phenotype of heart failure (HF) based on an ejection fraction (EF) of between 40% and 49%, namely HF with mid-range EF (HFmrEF), has fuelled investigations into the clinical profile and prognosis of this ...
Davide Margonato   +6 more
doaj   +2 more sources

Trajectories of Waist-to-Hip Ratio and Adverse Outcomes in Heart Failure with Mid-Range Ejection Fraction [PDF]

open access: yesObesity Facts, 2020
Background: Waist-to-hip ratio (WHR) is a strong predictor of mortality in patients with heart failure (HF). However, common WHR trajectories are not well established in HF with mid-range ejection fraction (HFmrEF) persons, and their relationship to ...
Feng Gao   +5 more
doaj   +2 more sources

Heart failure with mid‐range ejection fraction: characterization of patients from the PINNACLE Registry® [PDF]

open access: yesESC Heart Failure, 2019
Aims Guidelines for management of patients with heart failure with mid‐range ejection fraction [HFmrEF; left ventricular EF (LVEF) 41–49%] do not exist. Disagreement exists whether HFmrEF should be considered a distinct group. The aim of this study is to
Nasrien E. Ibrahim   +7 more
doaj   +2 more sources

Particularities of Older Patients with Obstructive Sleep Apnea and Heart Failure with Mid-Range Ejection Fraction [PDF]

open access: yesMedicina, 2019
Background and objectives: Obstructive sleep apnea syndrome (OSAS) and heart failure (HF) are increasing in prevalence with a greater impact on the health system.
Carmen Loredana Ardelean   +6 more
doaj   +2 more sources

Silent Cerebral Infarctions with Reduced, Mid-Range and Preserved Ejection Fraction in Patients with Heart Failure

open access: yesArquivos Brasileiros de Cardiologia
Heart failure predisposes to an increased risk of silent cerebral infarction, and data related to left ventricular ejection fraction are still limited.
Márcia Maria Carneiro Oliveira   +7 more
doaj   +2 more sources

Heart Failure with Mid-range Ejection Fraction: Lessons from CHARM. [PDF]

open access: yesCard Fail Rev, 2018
The newly defined category of heart failure (HF) with mid-range ejection fraction (HFmrEF; EF 40-49 %) is beginning to be characterised but little is known about the potential for treating it.
Lund LH.
europepmc   +2 more sources

Home - About - Disclaimer - Privacy